Diabetes made it famous. Longevity made it interesting again.
FDA-approved generic metformin ER with decades of metabolic use and a serious place in the longevity conversation.
About 10 minutes. No charge unless your clinician approves.
Old medicine. Very current biology.
Metformin is an FDA-approved generic medication with one of the longest clinical track records in modern medicine. It reduces the amount of glucose your liver releases, improves how sensitively your tissues respond to insulin, and activates AMPK, a cellular energy-sensing pathway involved in metabolic housekeeping throughout the body. It does its work steadily and without theatrics.
The extended-release formulation matters. Standard metformin has a reputation for stomach upset; the ER tablet releases gradually and is used in part to improve gastrointestinal tolerability, while once-daily dosing keeps the routine simple. Beyond its established metabolic uses, metformin is actively studied in longevity research, and your provider can discuss honestly what that evidence does and does not yet show.
Metformin is more than its diabetes origin. Its metabolic mechanisms and longevity research continue to attract serious study, while the ER formulation offers gradual release and a straightforward once-daily routine.
Read the evidence →For people who think a long track record is a feature.
The Metabolic Drift Patient
Glucose or A1C is moving in the wrong direction and you want the conversation grounded in established medicine rather than waiting for a small problem to become a dramatic one.
The Longevity Reader With Standards
You have seen metformin discussed everywhere from research papers to podcasts. You want a clinician who can separate the legitimate research interest from the conclusion that healthy people have already been proven to live longer on it.
The Foundation Builder
Training and nutrition matter, and you want the medical layer underneath them to be equally unglamorous and dependable. Metformin appeals precisely because it does not need to be the newest thing in the room.
Metformin ER is an FDA-approved generic medication. Its use for longevity is off-label. Candidacy is determined by your provider from your assessment, your history, and labs where they are indicated.
This might not be the right fit if:
- Severe renal impairment (eGFR below 30)
- Metabolic acidosis, including diabetic ketoacidosis
- Significant hepatic impairment or heavy alcohol use
- Acute conditions that can compromise kidney function, including severe dehydration or recent iodinated contrast, until cleared ## Updated copy: Hair and Skin
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Metformin ER, prescribed with care.
FDA-approved generic medication. Prescribed by a licensed provider after clinical review.
- FDA-approved generic metformin in an extended-release formulation
- Clinician reviews kidney function, medication history, and metabolic context before prescribing
- Dose and schedule directed by your provider
- Lab monitoring used where clinically indicated
- Ongoing clinician oversight through the treatment plan
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Metabolic.
Semaglutide
A clinician on the other end of every dose.
Compounded semaglutide injection with clinician review, pharmacy fulfillment, shipping, and follow-up inside one care model. (Contains semaglutide.)
Tirzepatide
Two incretin pathways. One physician watching both.
Compounded tirzepatide injection built around dual GIP and GLP-1 receptor biology with clinician-directed dosing and follow-up. (Contains tirzepatide.)
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
What the research shows
The approved use is type 2 diabetes, as an adjunct to diet and exercise.
The detail
Metformin extended-release is an FDA-approved generic, and the approved indication is specific: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, starting at 500 mg once daily with the evening meal and increasing to a maximum of 2000 mg once daily. The labeling carries a boxed warning about lactic acidosis.1
In overweight people with type 2 diabetes, all-cause mortality fell 36 percent.
The detail
In UKPDS 34, 342 overweight patients with newly diagnosed type 2 diabetes were randomly assigned to intensive blood-glucose control with metformin and followed for a median of 10.7 years; compared with conventional diet-first management, they had risk reductions of 32 percent for any diabetes-related endpoint, 95 percent confidence interval 13 to 47, 42 percent for diabetes-related death, 9 to 63, and 36 percent for all-cause mortality, 9 to 55.2
Metformin cut new diabetes by 31 percent; the lifestyle program cut it by 58.
The detail
In the Diabetes Prevention Program, 3234 adults without diabetes but with elevated fasting and post-load glucose were randomized to placebo, metformin 850 mg twice daily, or an intensive lifestyle program; over an average of 2.8 years metformin reduced the incidence of diabetes by 31 percent, 95 percent confidence interval 17 to 43, while the lifestyle program reduced it by 58 percent, 48 to 66, and was significantly more effective than metformin.3
At 15 years incidence stayed lower, but microvascular outcomes did not differ.
The detail
Across 15 years of follow-up in the Diabetes Prevention Program Outcomes Study, the metformin group still had 18 percent lower diabetes incidence than placebo, hazard ratio 0.82, 95 percent confidence interval 0.72 to 0.93, but the prevalence of the aggregate microvascular outcome at the end of the study did not differ between groups: 12.4 percent on placebo, 13.0 percent on metformin and 11.3 percent on lifestyle.4
The longevity signal is observational, not randomized.
The detail
The longevity signal is observational rather than randomized. In a retrospective analysis of UK primary-care records covering 78,241 people started on metformin monotherapy and 90,463 matched people without diabetes, adjusted median survival time was 15 percent lower in the matched non-diabetic controls than in the people taking metformin, survival time ratio 0.85, 95 percent confidence interval 0.81 to 0.90.5
What it does not show
No randomized trial has tested metformin in metabolically healthy adults.
The detail
Diabetes evidence is not longevity evidence. Every randomized result above comes from people who already had type 2 diabetes or had glucose elevated enough to put them at high risk of it. No randomized trial has tested whether metformin extends life or delays age-related disease in metabolically healthy adults.1234
TAME, the trial meant to answer that question, has published nothing a decade later.
The detail
The trial designed to answer that question has not reported. TAME was described by its investigators in 2016 as a plan to enroll 3000 subjects aged 65 to 79 at approximately 14 US centers and to measure time to a composite outcome of cardiovascular events, cancer, dementia and mortality. A decade later it has published no findings and has no entry in the ClinicalTrials.gov registry.6
Neither observational result compares metformin against placebo, and causality cannot be inferred.
The detail
Observational comparisons cannot separate the medication from the people who are prescribed it. The UK records analysis compared people prescribed metformin with matched controls in a database rather than in a trial, and a 2025 target trial emulation in the Women’s Health Initiative that found a 30 percent lower risk of death before age 90 with metformin, hazard ratio 0.70, 95 percent confidence interval 0.56 to 0.88, compared metformin against a sulfonylurea rather than against placebo, with its authors stating that causality cannot be inferred.57
In healthy older adults, metformin blunted the benefits of exercise.
The detail
In healthy older adults, metformin blunted the benefits of exercise. In a 12-week double-blind randomized trial in 53 adults averaging 62 years, metformin attenuated the increase in whole-body insulin sensitivity and in VO2 max after aerobic training and abrogated the training-related increase in skeletal muscle mitochondrial respiration.8 In a separate 14-week randomized, double-blind, placebo-controlled multicenter trial of progressive resistance training in 94 adults aged 65 and older, the placebo group gained more lean body mass and more thigh muscle mass than the metformin group.9
- FDA-approved prescribing information, metformin hydrochloride extended-release tablets, USP, Lupin Pharmaceuticals, Inc., label published June 2026.DailyMed
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on… Lancet. 1998.
- Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle… N Engl J Med. 2002.
- Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes… Lancet Diabetes Endocrinol. 2015.
- Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A… Diabetes Obes Metab. 2014.
- Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016.
- Shadyab AH, Espeland MA, Odegaard AO, et al. Comparative effectiveness of metformin versus sulfonylureas on… J Gerontol A Biol Sci Med Sci. 2025.
- Konopka AR, Laurin JL, Schoenberg HM, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise… Aging Cell. 2019.
- Walton RG, Dungan CM, Long DE, et al. Metformin blunts muscle hypertrophy in response to progressive… Aging Cell. 2019.
The labeling carries a boxed warning about lactic acidosis, a serious build-up of acid in the blood that has caused deaths in reported cases, and the warning signs it names are unusual tiredness, muscle aches, difficulty breathing, drowsiness and abdominal pain.
Do not use if you have
- An eGFR below 30
- Metabolic acidosis
Serious risks
- Long-term use can lower vitamin B12, which the labeling recommends checking periodically
Commonly reported
- Diarrhea, nausea and vomiting, the digestive effects that showed up more often than placebo in the trials behind the label
- Abdominal pain, bloating, heartburn, gas, headache and a change in taste, reported less often
That warning is why your provider reviews kidney function, liver health, alcohol intake, heart and lung conditions, age and any upcoming surgery or imaging study with contrast before prescribing. Metformin ER is an FDA-approved generic dispensed by a licensed US pharmacy, and candidacy is your clinician's call from your history and your labs.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Yes. Metformin has generated substantial observational research and prospective interest around aging-related outcomes, and its use for longevity is off-label. What that record does not yet establish is a definitive longevity benefit in healthy adults. The distinction matters because “being studied for longevity” and “proven to extend healthy life” are not interchangeable claims.
Provider review, your prescription if approved, pharmacy dispensing and shipping, and ongoing clinician oversight with messaging access. Lab work, when your provider recommends it, is discussed with you separately and transparently.
Gastrointestinal effects are the most common, including loose stools, nausea, or stomach upset. The ER formulation is used in part to improve tolerability. Long-term use can lower B12 levels, and kidney function matters because of the rare but serious risk of lactic acidosis. Your clinician reviews those factors before and during treatment.